mRNA Vaccine Core Enzyme Market to Reach USD 7 Billion by 2034
mRNA Vaccine Core Enzyme Market Overview 2025-2034
Luton, Bedfordshire, United Kingdom, June 16, 2025 (GLOBE NEWSWIRE) -- The global mRNA vaccine core enzyme market is witnessing unprecedented growth, driven by heightened demand for rapid vaccine development and growing advancements in biotechnology. As of 2024, the market is valued at approximately USD 2.3 billion, with projections indicating it will reach nearly USD 7 billion by 2034, reflecting a CAGR of 13.4% over the forecast period. This growth trajectory is underpinned by expanding applications of mRNA technology across infectious diseases, cancer therapeutics, and personalized medicine, along with increased public and private sector investments.
Download PDF Brochure: https://exactitudeconsultancy.com/request-sample/64421
The COVID-19 pandemic played a transformative role in bringing mRNA vaccine technologies into the spotlight, proving their potential for rapid response and scalable deployment. As governments, pharmaceutical companies, and research institutions pivot towards future pandemic preparedness and broader therapeutic applications, the core enzymes essential for mRNA synthesis and delivery—such as polymerases and lipid nanoparticles—are in increasingly high demand.
Market Segmentation Analysis
By Product Type
The market is segmented into Poly(A) Polymerase, RNA Polymerase, Nudge Enzyme, and Other Enzymes. Among these, Poly(A) Polymerase holds a dominant share due to its essential role in stabilizing synthetic mRNA transcripts for vaccine formulation. Enhanced purification techniques have also improved the quality and reliability of Poly(A) Polymerase, increasing its demand.
RNA Polymerase, equally critical, is widely used in transcription processes to synthesize mRNA from DNA templates. It finds applications in both commercial vaccine production and academic research. Nudge Enzymes, although newer to the market, are gaining traction due to their emerging role in improving mRNA stability and delivery efficiency. These innovations signal strong growth prospects, particularly for advanced research and personalized therapies.
By Application
The therapeutics segment is emerging as a key growth driver within the application spectrum, spurred by research into using mRNA technology for cancer treatment, autoimmune conditions, and rare diseases. Collaborations between biotech startups and large pharmaceutical firms are fostering the development of new therapeutic platforms leveraging mRNA enzymes.
In contrast, preventive vaccines remain the cornerstone of the mRNA enzyme market, bolstered by ongoing global vaccination programs and the anticipation of future pandemics. The success of COVID-19 mRNA vaccines has underscored the need for faster, adaptable vaccine platforms.
Research and development (R&D) also constitutes a significant market share. A surge in clinical trials and funding for pre-clinical mRNA studies—especially in academic and research institutions—continues to drive enzyme demand, particularly as R&D efforts expand to newer disease areas.
By End User
Pharmaceutical companies form the largest end-user segment, leveraging their production capacity, regulatory expertise, and global distribution networks to manufacture large volumes of mRNA-based products. These firms rely heavily on high-quality enzymes for consistent vaccine efficacy.
Academic and research institutions, while smaller in scale, play a vital role in early-stage innovation and pilot studies. They frequently collaborate with biotech firms to explore novel mRNA applications, thereby fueling demand for research-grade enzymes.
Biotech companies, particularly startups focused on gene editing and personalized medicine, represent a fast-growing end-user base. These companies require scalable and customizable enzyme solutions, thereby creating a niche yet dynamic demand profile.
By Technology
The market is further categorized by technology into In Vitro Transcription, Purification Technologies, and Quality Control and Characterization Technologies. Among these, In Vitro Transcription (IVT) is foundational to mRNA synthesis. Continued optimization has enhanced both yield and cost-efficiency, making IVT indispensable for vaccine production.
Purification technologies ensure removal of contaminants and increase product stability. Emerging trends involve automating these processes to minimize human error and improve throughput.
Meanwhile, quality control and characterization technologies are becoming increasingly vital due to stringent regulatory requirements. These technologies facilitate consistency, batch reproducibility, and compliance, making them a key area for future investments.
By Distribution Channel
Distribution of mRNA enzymes occurs through direct sales, online platforms, and third-party distributors. Direct sales remain preferred by pharmaceutical companies for custom orders and quality assurance, ensuring close coordination with enzyme manufacturers.
However, online sales are on the rise, particularly among academic institutions and smaller biotech firms looking for convenience and cost savings. The trend reflects a broader shift toward digital procurement models in the life sciences sector.
Third-party distributors serve an important role in extending enzyme availability to emerging markets and underserved regions. Their reach and logistical support are critical to ensuring timely supply in areas lacking direct access to manufacturers.
Browse full Report - https://exactitudeconsultancy.com/reports/64421/global-mrna-vaccine-core-enzyme-market
Market Segmentation
By Product Type - Poly(A) Polymerase - RNA Polymerase - Nudge Enzyme
By Application - Therapeutics - Preventive Vaccines - Research and Development
By End-user - Pharmaceutical Companies - Academic and Research Institutions - Biotech Companies
By Distribution Channel - Direct Sales - Online Sales - Third-party Distributors
By Technology - In Vitro Transcription - Purification technologies - Quality control and characterization technologies
By Region - North America - Europe - Asia Pacific - Latin America - Middle East and Africa
Regional Insights
North America
North America leads the global mRNA vaccine core enzyme market, contributing approximately 45% of global revenue in 2024. The U.S. stands at the forefront due to its robust biotech ecosystem, deep investment in R&D, and support from regulatory bodies like the FDA. Strategic collaborations between pharma giants and research institutions further accelerate innovation and commercialization. The region is expected to grow at a CAGR of around 8.5% through 2034.
Europe
Europe holds a significant market share of around 30%, led by countries like Germany, the UK, and France. Favorable government policies, strong academic research infrastructure, and a growing emphasis on biotechnology are propelling market growth. A CAGR of 7.0% is anticipated through 2034 as EU nations enhance their domestic vaccine capabilities and biotech investments.
Asia Pacific
Asia Pacific is the fastest-growing region, projected to expand at a CAGR of 10.5% by 2034. Major drivers include rising investments in health infrastructure, expanding pharmaceutical manufacturing hubs in China and India, and increasing public health awareness. However, challenges such as regulatory complexity and uneven infrastructure persist across the region.
Latin America and Middle East & Africa
Emerging markets like Latin America and Africa are exhibiting strong growth potential, driven by improvements in public health funding and localized vaccine production. Though still nascent, these regions are expected to attract future investment. Infrastructure and regulatory challenges, however, may temper the pace of growth unless addressed through public-private collaboration.
Buy Now: https://exactitudeconsultancy.com/purchase/?currency=USD&type=single_user_license&report_id=64421
Key Competitors
Moderna Inc.
BioNTech SE
Pfizer Inc.
CureVac AG
Gennova Biopharmaceuticals
Zydus Cadila
Sanofi
AstraZeneca
Merck & Co., Inc.
Novavax Inc.
Regeneron Pharmaceuticals
Translate Bio
Genexine Inc.
AbCellera Biologics
Takeda Pharmaceutical Company Limited
Recent Market Developments
Moderna Inc. expanded its mRNA production facility in Norwood, Massachusetts in August 2023, aiming to scale up production in response to growing global demand.
BioNTech SE launched a next-generation mRNA-based influenza vaccine in September 2023, signaling a shift toward seasonal applications beyond COVID-19.
CureVac AG announced a strategic partnership in July 2023 with a major pharmaceutical firm to co-develop mRNA therapies, highlighting a trend toward collaboration and shared risk.
Zydus Cadila received regulatory approval in India for its mRNA COVID-19 vaccine in October 2023, positioning the country as a significant player in localized mRNA production.
Pfizer Inc. acquired a biotech firm specializing in advanced mRNA platforms in November 2023, bolstering its pipeline and reaffirming its commitment to innovation.
This report is also available in the following languages : Japanese (mRNAワクチンコア酵素市場), Korean (mRNA 백신 핵심 효소 시장), Chinese (mRNA疫苗核心酶市场), French (Marché des enzymes de base des vaccins à ARNm), German (Markt für mRNA-Impfstoff-Kernenzyme), and Italian (Mercato degli enzimi fondamentali del vaccino mRNA), etc.
Request Sample Pages: https://exactitudeconsultancy.com/reports/64421/global-mrna-vaccine-core-enzyme-market#request-a-sample
More Research Finding –
Tozinameran Market
The global market for Tozinameran, a key COVID-19 mRNA vaccine, is valued at approximately $21 billion. The market is expected to grow significantly, with a projected value of around $45 billion by 2034. This represents a Compound Annual Growth Rate (CAGR) of about 8.1% from 2025 to 2034.
https://exactitudeconsultancy.com/reports/66480/tozinameran-market
mRNA Vaccine and Therapeutics Raw Material Market
The global market for mRNA vaccine and therapeutics raw materials is valued at approximately $4.5 billion, driven by the accelerating demand for innovative vaccine solutions and therapeutic modalities. The market is projected to reach around $9.2 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of approximately 8.2% from 2025 to 2034.
https://exactitudeconsultancy.com/reports/65932/mrna-vaccine-and-therapeutics-raw-material-market
Non-invasive Vaccine Market
The global non-invasive vaccine market is projected to reach a value of approximately $2.5 billion in 2024, driven by advancements in vaccine delivery systems and increasing demand for pain-free immunization methods. During the forecast period from 2025 to 2034, the market is expected to experience significant growth, with an estimated compound annual growth rate (CAGR) of 11.5%.
https://exactitudeconsultancy.com/reports/59766/global-non-invasive-vaccine-market
Foot and Mouth Disease FMD Vaccines for Pig Market
The global market for Foot and Mouth Disease (FMD) vaccines for pigs is projected to reach approximately $1.2 billion in 2024, with a significant growth trajectory anticipated through the next decade. By 2034, the market value is expected to rise to about $2.3 billion, reflecting a robust Compound Annual Growth Rate (CAGR) of 6.9% from 2025 to 2034.
https://exactitudeconsultancy.com/reports/59747/global-foot-and-mouth-disease-fmd-vaccines-for-pig-market
Flu RNA Vaccines Market
The global market for flu RNA vaccines is valued at approximately $2.5 billion, reflecting a growing demand for innovative vaccination solutions amid rising flu cases and the ongoing need for enhanced public health measures. Projections indicate that the market will expand to around $6 billion by 2034, with a Compound Annual Growth Rate (CAGR) of 9.1% over the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/55918/global-flu-rna-vaccines-market
Pediatric Vaccines Market
The global pediatric vaccines market is valued at approximately $40 billion, driven by increasing immunization rates and the growing incidence of infectious diseases among children. With advancements in vaccine technologies and rising awareness of preventive healthcare, the market is projected to reach around $70 billion by 2034, marking substantial growth.
https://exactitudeconsultancy.com/reports/52011/pediatric-vaccines-market
Shingles Vaccine Market
The global shingles vaccine market is valued at approximately $5.1 billion, driven by increasing awareness of shingles and rising vaccination rates among older populations. The market is projected to grow significantly, reaching an estimated value of $10 billion by 2034, with a Compound Annual Growth Rate (CAGR) of 7.1% from 2025 to 2034.
https://exactitudeconsultancy.com/reports/51861/shingles-vaccine-market
U.S. Meningococcal Vaccines Market
The U.S. meningococcal vaccines market is valued at approximately $1.5 billion, reflecting a robust demand driven by increasing awareness of meningococcal disease and vaccination initiatives. The market is projected to grow at a CAGR of 6.2%, reaching an estimated $2.7 billion by 2034. This growth trajectory is propelled by several factors, including expanded recommendations for vaccination among adolescents and young adults, and the ongoing efforts to enhance vaccine accessibility and education.
https://exactitudeconsultancy.com/reports/50804/u-s-meningococcal-vaccines-market
Rna Based Therapeutics Market
The RNA-based therapeutics market is projected to reach a value of approximately $7.3 billion in 2024, driven by advancements in mRNA technology and increasing investments in gene therapies. The market is expected to expand significantly with a projected value of around $19.6 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 10.4% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/50749/rna-based-therapeutics-market
U.S. Vaccine Technologies Market
The U.S. vaccine technology market is valued at approximately $70 billion, buoyed by increasing demand for innovative vaccines and heightened awareness of public health needs. The market is projected to grow significantly, with an estimated value reaching $110 billion by 2034, reflecting a robust growth trajectory.
https://exactitudeconsultancy.com/reports/50446/u-s-vaccine-technologies-market
Chikungunya Vaccine Future Trends and Market
The global chikungunya vaccine market is projected to hold a value of approximately $2.5 billion in 2024. Given the increasing incidence of chikungunya virus infections and the growing awareness regarding preventative healthcare measures, the market is expected to reach around $5.6 billion by 2034. This outlook suggests a robust Compound Annual Growth Rate (CAGR) of 8.5% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/50225/chikungunya-vaccine-market
Innovations in Vaccine Technologies Market
The global vaccine technologies market is projected to reach a value of approximately $65 billion in 2024, with expectations to grow to about $110 billion by 2034. This trajectory represents a compound annual growth rate (CAGR) of around 5.3% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/50217/vaccine-technologies-market
Dendritic Cell Therapy Vaccine Market
The dendritic cell therapy vaccine market is valued at approximately $1.2 billion, reflecting a robust interest in innovative immunotherapy solutions. The market is projected to reach around $3.4 billion by 2034, indicating a substantial growth trajectory driven by advancements in personalized medicine and an increasing prevalence of cancer worldwide.
https://exactitudeconsultancy.com/reports/66582/dendritic-cell-therapy-vaccine-market
Gammaretroviral Vector Market
The gammaretroviral vector market is anticipated to reach approximately $1.2 billion in 2024, driven by advancements in gene therapies and increasing applications in biomedical research. The market is projected to grow significantly, with an estimated compound annual growth rate (CAGR) of 8.5% from 2025 to 2034, ultimately reaching around $2.7 billion by the end of this forecast period.
https://exactitudeconsultancy.com/reports/66577/gammaretroviral-vector-market
Multi Use Bioreactor Market
The global multi-use bioreactor market is valued at approximately $3.2 billion, reflecting significant growth driven by advances in biopharmaceutical manufacturing and increased demand for personalized medicine. The projected market value for 2025-2034 is estimated to reach $6.5 billion, highlighting the sector's robust expansion.
https://exactitudeconsultancy.com/reports/66574/multi-use-bioreactor-market
Medical Refrigerated Market
The global medical refrigerated market is valued at approximately $6.5 billion in 2024, with projections indicating a potential increase to around $10 billion by 2034. This growth reflects a robust Compound Annual Growth Rate (CAGR) of approximately 4.5% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/66520/medical-refrigerated-market
Needle for Disposable Injection Pen Market
The disposable injection pen market is valued at approximately $4.5 billion in 2024, with expectations to grow significantly over the next decade, reaching an estimated $9 billion by 2034. This growth reflects a Compound Annual Growth Rate (CAGR) of around 7.5% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/66462/needle-for-disposable-injection-pen-market
Meningitis B Vaccine Market
The global market for Meningitis B vaccines is valued at approximately $1.1 billion. Projections indicate robust growth, with the market expected to reach $2.4 billion by 2034, driven by increasing awareness of preventive healthcare and advancements in vaccine technology. This represents a Compound Annual Growth Rate (CAGR) of around 8.2% from 2025 to 2034.
https://exactitudeconsultancy.com/reports/65956/meningitis-b-vaccine-market
Human Papillomavirus Vaccine Types 16 18 Market
The global market for Human Papillomavirus (HPV) vaccines, particularly those aimed at preventing types 16 and 18, is valued at approximately $3 billion. The market is projected to reach around $5 billion by 2034, reflecting heightened awareness of HPV-related health risks and increased vaccination initiatives worldwide.
https://exactitudeconsultancy.com/reports/65955/human-papillomavirus-vaccine-types-16-18-market
CONTACT: Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@exactitudeconsultancy.comSign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Atlantic
an hour ago
- Atlantic
RFK Jr. Is Globalizing the Anti-Vaccine Agenda
This week, Robert F. Kennedy Jr. used his address to a global vaccine summit to disparage global vaccination. The conference was organized by Gavi, the world's leading immunization program, and in a recorded speech, Kennedy accused the organization of collaborating with social-media companies to stifle dissenting views on immunization during the coronavirus pandemic and said it had 'ignored the science' in its work. He criticized Gavi for recommending COVID-19 shots to pregnant women, and went deep on a discredited study that purported to find safety issues with a tetanus vaccine commonly used in the developing world. 'In its zeal to promote universal vaccination,' Kennedy claimed, Gavi 'has neglected the key issue of vaccine safety.' Kennedy's remarks confirmed what The New York Times first reported in March: that the United States, Gavi's third-largest donor, would stop pledging money to the organization. (Congress, which has always had final say over Gavi funding, has not yet weighed in.) They are also the first indication that the U.S.'s rejection of global vaccine campaigns stems from the Trump administration's opposition not only to foreign aid, but to vaccination itself. For the first time, Kennedy has managed to use the anti-vaccine agenda to guide American foreign policy. Gavi, at its most basic level, is Costco for immunizations, wielding its massive purchasing power to buy vaccines in bulk for cheap. National governments and private philanthropies pledge funding to it every five years. The United Kingdom and the Gates Foundation are its largest donors; the United Nations distributes the shots. The poorest countries pay 20 cents per vaccine, and prices rise along with national income. Since the partnership was launched, in January 2000, 19 countries —including Ukraine, Congo, and Guyana—have gone from relying on Gavi to paying for vaccinations entirely on their own. Indonesia, which accepted donations from Gavi as recently as 2017, pledged $30 million to the organization this funding cycle. Gavi, by its own estimate, has saved about 19 million lives and vaccinated 1 billion children. At the conference this week, the director of the World Health Organization noted that since 2000, the number of children who die each year before they reach the age of 5 has fallen by more than half, largely due to the power of vaccines. By Gavi's estimates, the U.S. canceling its Biden-era pledge to provide $1.2 billion this donation cycle could lead to the deaths of more than 1 million children who otherwise would have lived. (The Department of Health and Human Services did not respond to a request for comment.) In his recorded remarks, Kennedy said America would not send the money until Gavi can 're-earn the public trust' by 'taking vaccine safety seriously.' Cutting off millions of children's only access to routine vaccines is 'the most emphatic globalization of the anti-vaxxer agenda,' Lawrence Gostin, the faculty director of Georgetown's O'Neill Institute for National and Global Health Law, told me. Tom Frieden, the former director of the CDC, told me that after he heard Kennedy's remarks, 'I was literally sick to my stomach,' because 'unscientific, irresponsible statements like this will result in the deaths of children.' (The U.S. has run an international anti-vaccine campaign before: According to an investigation by Reuters, in 2020, the Pentagon unleashed bot accounts on multiple social-media platforms that impersonated Filipinos and discouraged uptake of China's Sinovac vaccine—the first COVID vaccine available in the Philippines—using a hashtag that read, in Tagalog, 'China is the virus.' The goal was not to combat vaccines, but to undermine China's influence.) Kennedy's prerecorded address held back his harshest critiques of Gavi. In his 2021 book, The Real Anthony Fauci, Kennedy paints 'Bill Gates's surrogate group Gavi' (the Gates Foundation co-founded Gavi) as nothing more than a profiteering 'cabal' and a facilitator of 'African Genocide.' To hear Kennedy tell it, 'virtually all of Gates's blockbuster African and Asian vaccines—polio, DTP, hepatitis B, malaria, meningitis, HPV, and Hib—cause far more injuries and deaths than they avert.' Decades' worth of safety and efficacy studies have proved him wrong. In his remarks to Gavi this week, Kennedy focused on the DTP (diphtheria, tetanus, and pertussis) shot, describing at length a 'landmark' 2017 study that found the vaccine increased all-cause mortality among girls in Guinea-Bissau. But as Frieden pointed out, this was in fact a relatively small observational study. In 2022, a randomized, double-blind, placebo-controlled trial of more than 50,000 newborns found that the DTP vaccine significantly decreased infant mortality. Frieden compared the evidence: 'Hundreds of kids versus 50,000 kids. Poorly done; well done.' Kennedy made efforts to take his anti-vaccine advocacy global before he became America's health secretary. In 2021, he delivered a webinar on the importance of expanding an 'international movement' for Children's Health Defense, the anti-vaccine organization he founded. In 2019, when Samoa was experiencing a major dip in measles immunization after an improperly prepared vaccine killed two children, Kennedy visited the prime minister and, on behalf of Children's Health Defense, reportedly offered to build an information system the country could use to track the health effects of vaccines and other medical interventions. When a deadly measles outbreak took hold later that year, Kennedy sent a letter to the prime minister suggesting that widespread vaccination might make unvaccinated Samoan children more likely to die of measles. (In an interview for a 2023 documentary, Kennedy said that 'I had nothing to do with people not vaccinating in Samoa' and that his conversations about vaccines with the prime minister had been 'limited.') Now, it seems, Kennedy has gained the power to realize his ambitions both domestically and abroad. Earlier this month, Kennedy dismissed all 17 members of the CDC's vaccine advisory committee, then replaced them with a group that includes several allies who have spread misinformation about the harms of vaccines. This week, as other countries pledged their support for Gavi, Kennedy's brand-new, handpicked panel convened for a discussion of the dangers of thimerosal, a vaccine ingredient that is a frequent target of anti-vaxxers despite having been found safe. The committee has formed a working group to review the 'cumulative effect' of childhood vaccination in the United States. As Kennedy said in his address to Gavi, 'Business as usual is over.'
Business Upturn
an hour ago
- Business Upturn
GradGuard Honors National Insurance Awareness Day by Awarding $15,000 in Scholarships to College Students
By GlobeNewswire Published on June 28, 2025, 19:30 IST PHOENIX, June 28, 2025 (GLOBE NEWSWIRE) — GradGuard, the authority in helping protect students and their families from the risks of college life through its pioneering tuition and renters insurance programs, is pleased to announce the winners of its inaugural scholarship program, awarding $3,000 each to five outstanding students across the country. As part of its mission to help schools educate and protect students from the risks of college life, GradGuard launched the no-essay scholarship program to highlight the importance of being prepared for the unexpected. With nearly 600 applicants nationwide, the five winners were selected for their content, creativity, and presentation style in sharing personal college experiences, stories, or real-world scenarios that demonstrate the value of tuition or renters protection to enable students to overcome common disruptions to college life. 'Hearing the authentic voices of students helps to demonstrate that the risks are real,' said John Fees, GradGuard's co-founder. 'With nearly 2,000 annual campus fires and more than 22,000 crimes reported annually the value of renters insurance to protect students from theft or damages is a vital consideration, while tuition insurance can helps to safeguard their financial investment if they need to withdraw for a covered reason such as an accident, injury or physcal or mental health condition.' 2025 Scholarship Winners: Emily Goldner-Morgan, Boise State University Jazmin Goodwin, Arizona State University Kara Haj, University of California, Los Angeles Wes Orr, Abilene Christian University Michael Seepersaud, Georgian Court University Each student will receive $3,000 to help offset tuition, books, housing, or other college-related expenses. National Insurance Awareness Day, observed annually on June 28, serves as a vital reminder for the nearly 20 million college students to assess their insurance needs and ensure adequate protection against the unique risks of college life. GradGuard's scholarship program and its work with more than 650 colleges and universities help to promote greater financial literacy and enable students to make smart decisions to protect themselves from financial risks that can otherwise disrupt their education. 'We believe in investing directly in students, and our scholarship program is a testament to that commitment,' adds Fees. 'Congratulations to Emily, Jazmin, Kara, Wes, and Michael. We are incredibly proud to support their academic pursuits and wish them all the best.' For more information about GradGuard's college renters and tuition insurance programs, and to learn about future scholarship opportunities, please visit About GradGuard: GradGuard is the authority on helping schools educate and protect students from the risks of college life. As the #1 source of college tuition and renters insurance, GradGuard's pioneering protections have served more than 1.8 million students at more than 1,900 unique institutions. To learn more, visit Attachment GradGuard's 2025 Scholarship Recipients Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
an hour ago
- Business Upturn
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Apple Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action
NEW YORK, June 28, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Apple Inc. (NASDAQ: AAPL) between June 10, 2024 and June 9, 2025, both dates inclusive (the 'Class Period'). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 19, 2025. SO WHAT: If you purchased Apple securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Apple class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 19, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) Apple misstated the time it would take to integrate the advanced AI-based Siri features into its devices; (2) accordingly, it was highly unlikely that these features would be available for the iPhone 16; (3) the lack of such advanced AI-based features would hurt iPhone 16 sales; (4) as a result, Apple's business and/or financial prospects were overstated; and (5) as a result, Apple's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Apple class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ——————————- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]
